azn201406186k2.htm



FORM 6-K


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of  June 2014

Commission File Number:  001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X            Form 40-F  __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):            

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  __                 No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):   82-_____________
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 
   
1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:ii
AstraZeneca PLC
2 Reason for the notification
(please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
Yes
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
No
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
No
An event changing the breakdown of voting rights
No
Other (please specify):
    
3. Full name of person(s) subject to the
notification obligation:iii
Invesco Limited
4. Full name of shareholder(s)
 
(if different from 3.):iv
  
5. Date of the transaction and date on
which the threshold is crossed or
reached:v
17 April 2014
6. Date on which issuer notified:
17 June 2014
7. Threshold(s) that is/are crossed or
reached:vi, vii
5%

 
8. Notified details:
A: Voting rights attached to sharesviii, ix
Class/type of
shares
 
if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of shares
Number of voting
rights
% of voting rights x
Direct
Directxi
Indirectxii
Direct
Indirect
Ordinary Shares
72,920,319
72,920,319
    
63,033,761
  
4.99%
GB0009895292
 
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
Expiration
datexiii
Exercise/
Conversion Periodxiv
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
% of voting
rights
         
 
C: Financial Instruments with similar economic effect to Qualifying Financial Instrumentsxv, xvi
Resulting situation after the triggering transaction
Type of financial
instrument
Exercise price
Expiration datexvii
Exercise/
Conversion periodxviii
Number of voting rights instrument refers to
% of voting rightsxix, xx
         
Nominal
Delta
   
 
Total (A+B+C)
Number of voting rights
Percentage of voting rights
63,033,761
4.99%

 
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:xxi
Invesco Advisers Inc. - 182,047
Invesco Asset Management Japan - 75,034
Invesco Asset Management Limited - 16,790,150
Invesco Asset Management S.A (France) - 76,196
Invesco PowerShares Capital Management LLC - 158,278
Invesco GT Management Ltd - 39,146
Invesco Hong Kong Limited - 1,155
Invesco Fund Managers Limited - 45,006,926
Invesco Asset Management Limited GmbH - 667,087
Van Kampen Asset Management - 37,742
 
Proxy Voting:
10. Name of the proxy holder:
Invesco Limited
11. Number of voting rights proxy holder will cease
to hold:
N/A
12. Date on which proxy holder will cease to hold
voting rights:
N/A
 
 
13. Additional information:
  
14. Contact name:
Sam Edwards
15. Contact telephone number:
01491 416381

 
 

 
SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC




Date: 18 June 2014
By:  /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary